コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 The majority of donor recipient pairs were HLA mismatched (4.6+/-1.2 of the six major HLA antigens)
7 rom those mediating GVL in each of the eight HLA-mismatched and one HLA-matched donor/recipient pairs
8 CT recipients, including 125 cord blood, 125 HLA-mismatched, and 154 HLA-matched HCTs, detection of m
9 d T-replete grafts, 97% received marrow, 95% HLA-mismatched, and 97% received calcineurin-based graft
11 merism can be induced in adult recipients of HLA-mismatched bone-marrow transplantation by a non-myel
12 aft survival for 7614 HLA-matched and 81,364 HLA-mismatched cadaveric kidney transplantations reporte
16 hanisms for this, we compared the ability of HLA-mismatched CB and adult peripheral blood (PB) T cell
17 tologous DC, Mtb-infected autologous DC, and HLA-mismatched CD1+ targets (DC), as well as HLA-mismatc
23 ing KIR ligand' might not be limited only to HLA mismatched donor-recipient combinations but may be a
24 sed risk of sclerosis included the use of an HLA-mismatched donor and a major ABO-mismatched donor.
25 nosis of acute leukemia, a transplant from a HLA-mismatched donor and from cord blood, older age, and
31 patients who received transplantations from HLA-mismatched donors (39.5% +/- 10.4%, P <.05) or HLA-m
34 ografts and/or transplants from unrelated or HLA-mismatched donors seem to be predominantly affected.
35 suggest that myeloablative conditioning and HLA-mismatched donors should be avoided in future protoc
36 ation of WT1-specific T cells generated from HLA-mismatched donors should be performed with appropria
40 ed EBV-specific CTL to autologous but not to HLA-mismatched EBV+ tumors as early as 24 h after intrav
41 traperitoneally with autologous but not with HLA-mismatched EBV-LCL had significantly improved surviv
42 with grafts that were HLA-matched (n=35) or HLA-mismatched for one (n=201) or two antigens (n=267) (
43 uiescence (operational tolerance) against an HLA-mismatched graft, allowing them to withdraw all immu
45 allografts increases the risk of failure of HLA-mismatched grafts during the first year after transp
46 disease, the risk of death was higher in the HLA-mismatched group than in the cord-blood group (hazar
47 associations was lower (hazard ratio in the HLA-mismatched group, 1.28; 95% CI, 0.51 to 3.25; P=0.60
48 azard ratios were lower (hazard ratio in the HLA-mismatched group, 1.36; 95% CI, 0.76 to 2.46; P=0.30
49 in the cord-blood group (hazard ratio in the HLA-mismatched group, 3.01; 95% CI, 1.22 to 7.38; P=0.02
50 n of multiple viruses included cord blood or HLA-mismatched HCT, myeloablative conditioning, and acut
52 o being applied to permit transplantation of HLA mismatched hematopoietic stem cells to patients with
53 ) transgenic mice and in patients undergoing HLA-mismatched hematopoietic cell transplantation (HCT),
54 titution while limiting alloreactivity after HLA-mismatched hematopoietic stem cell transplantation,
55 developed a single human leukocyte antigen (HLA)-mismatched heterotopic murine heart transplant mode
56 -CD25 immunotoxin following stimulation with HLA-mismatched host LCLs more consistently depleted in v
58 s in HIV-1 that persist upon transmission to HLA-mismatched hosts may spread in the population as the
62 s from two patients were cotransplanted with HLA-mismatched human islets into immunodeficient mice.
63 lls) was alloantigen-specific expanded using HLA-mismatched immature, mature monocyte-derived dendrit
65 gical rejection of Human Leukocyte Antigens (HLA)-mismatched induced pluripotent stem cells (iPSCs) l
67 However, the 5-year graft survival rate in HLA-mismatched kidneys without DGF was significantly hig
70 ly higher killing of autologous LCLs than of HLA-mismatched LCLs (mean, 56% vs. 14% at 20:1 ratio).
71 31, p=0.0003) and possibly after one-antigen HLA-mismatched low-cell-dose umbilical-cord-blood transp
72 100(+) HLA-matched melanoma targets, but not HLA-mismatched melanoma or gp100(-) nonmelanoma tumor li
73 ture of the same target cells with activated HLA-mismatched mitogen-activated lymphomononuclear cells
77 n followed by donor-recipient inhibitory KIR-HLA mismatched NK cells is well tolerated by patients an
78 n-like receptor-human leukocyte antigen (KIR-HLA) mismatched NK cells (median, 29 x 10(6)/kg NK cells
79 bearing both the autologous and either fully HLA-mismatched or genotypically related haplotype-sharin
80 Transplantation using T-cell depletion or HLA-mismatched or umbilical cord donors was also exclude
82 patients, partially human leukocyte antigen (HLA)-mismatched, or HLA-haploidentical, related donor bo
86 aluable patients in group 2, the regimen for HLA-mismatched patients was changed in 1984 to include C
89 y results of transplantation using partially HLA-mismatched placental blood from unrelated donors.
90 HLA-matched family donors are available, but HLA-mismatched procedures are associated with substantia
96 crochimerism can be achieved without GVHD in HLA-mismatched recipients of combined kidney and hematop
97 llow-up in a phase IIb tolerance protocol in HLA-mismatched recipients of living donor kidney plus fa
98 l value of CREG matching observed in the one-HLA-mismatched recipients of the UNOS (but not the Pitts
99 ) with unrelated or human leukocyte antigen (HLA) mismatched related donor (relative risk [RR] = 4.1)
102 l-depleted marrow from an unrelated donor or HLA-mismatched related donor, the risk of developing lym
105 There were no differences in survival after HLA-mismatched related, HLA-matched unrelated, or mismat
106 Thirty-one patients received marrow from HLA-mismatched relatives who differed by one or more loc
107 d grafts from HLA-matched siblings, 13% from HLA-mismatched relatives, 12% from HLA-matched, and 41%
108 571 unique peripheral blood samples from 348 HLA-mismatched renal transplant recipients and 101 nontr
111 0), suggesting that the allograft of Class I HLA-mismatched seropositive donors is inaccessible to CD
117 ll receptors (TCRs) isolated from allogeneic HLA-mismatched TCR repertoires has, however, been impede
118 us EBV+ tumors, one autologous and the other HLA mismatched to the EBV-specific CTL donor, had regres
119 human histocompatibility leukocyte antigen (HLA)-mismatched, transformed, B lymphocyte cell lines (L
126 ecipients of 0 to 3 human leukocyte antigen (HLA)-mismatched UCB and HLA-A, B, DRB1-matched BM was pe
129 were higher after transplants of two-antigen HLA-mismatched umbilical cord blood (relative risk 2.31,
130 e use of HLA-matched and one- or two-antigen HLA-mismatched umbilical cord blood in children with acu
132 Relapse rates were lower after two-antigen HLA-mismatched umbilical-cord-blood transplants (0.54, p
133 or cord blood transplantation from partially HLA-mismatched units can cure many children with leukemi
134 ling (n = 1), HLA-matched unrelated (n = 9), HLA-mismatched unrelated (n = 3), and HLA haploidentical
139 s) undergoing transplantation with partially HLA-mismatched unrelated donor umbilical cord blood were
141 ymorphisms (SNPs) in 2628 patients and their HLA-mismatched unrelated donors to determine whether SNP
143 d CML CFU-GM comparably to effectors from 14 HLA-mismatched unrelated individuals (mean inhibition 42
144 hypothesis that removal of CD4 cells from an HLA-mismatched unrelated marrow graft would substantiall
145 cate that the adoptive transfer of partially HLA-mismatched virus-specific CTL is safe despite in vit
146 transplants where donors and recipients are HLA mismatched, we distinguish between donor liver-deriv
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。